目的:通过检测卵泡液中白血病抑制因子(LIF)及睾酮(T)的变化,探讨达英-35改善卵泡发育的机理。方法:选择40例PCOS患者作为研究对象,随机分为用药组和不用药组各20例,选择19例无排卵障碍的患者作为对照组。用药前后分别在B超引导下抽取卵泡液进行白血病抑制因子及睾酮的检测。结果:①用药干预前LIF浓度,用药组为(19.6±3.6)ng/L,对照组为(34.9±3.6)ng/L,用药组与对照组比较明显降低(P<0.05)。T浓度用药组为(8.3±0.9)μg/L,对照组为(5.0±1.1)μg/L,用药组较对照组明显升高(P<0.05)。不用药组LIF浓度为(19.4±3.2)ng/L,T浓度为(8.2±1.0)μg/L,用药组与不用药组LIF及T浓度比较无统计学差异。②用药干预后LIF及T浓度变化:用药组与对照组LIF浓度分别为(27.9±6.0)ng/L、(35.3±3.7)ng/L,用药组仍低于对照组(P<0.05);T浓度用药组与对照组分别为(7.2±1.3)μg/L、(5.1±0.9)μg/L。不用药组LIF浓度为(19.6±3.1)ng/L,用药组高于不用药组(P<0.05);但T浓度两组无差异。用药组用药后LIF浓度较用药前升高(P<0.05);T浓度变化不明显。③用药干预后卵泡发育情况与LIF及T浓度变化幅度的关系:用药组卵泡成熟者7例,卵泡液LIF浓度增加幅度为(16.3±3.2)ng/L,而未成熟者增加幅度为(7.4±1.5)ng/L,两者有统计学差异(P<0.05);T浓度则在成熟卵泡中下降幅度大于未成熟者,两者有统计学差异(P<0.05)。结论:达英-35改善卵泡液发育可能与改变卵泡中白血病抑制因子及睾酮的水平有关。 Objective: To explore the mechanism of da-Ying-35 improving follicular development by detecting the changes of leukemia inhibitory factor (LIF) and testosterone (T) in follicular fluid. Methods: Forty patients with PCOS were selected as study subjects. They were randomly divided into medication group and non-medication group, 20 cases each. Nineteen patients with no ovulation disorder were selected as control group. Before and after treatment were drawn under the guidance of B-follicular fluid leukemia inhibitory factor and testosterone. Results: ① The concentration of LIF before treatment was (19.6 ± 3.6) ng / L in the treatment group and (34.9 ± 3.6) ng / L in the control group, and was significantly lower in the treatment group than in the control group (P <0.05). T concentration was (8.3 ± 0.9) μg / L in treatment group and (5.0 ± 1.1) μg / L in control group, which was significantly higher than that in control group (P <0.05). The concentrations of LIF and T in non-medication group were (19.4 ± 3.2) ng / L and T (8.2 ± 1.0) μg / L, respectively. (2) The changes of LIF and T concentrations after treatment were as follows: the concentrations of LIF in treatment group and control group were (27.9 ± 6.0) ng / L and (35.3 ± 3.7) ng / L respectively, and were still lower than those in control group (P <0.05); The concentrations of T were (7.2 ± 1.3) μg / L and (5.1 ± 0.9) μg / L, respectively. The concentration of LIF in the untreated group was (19.6 ± 3.1) ng / L, which was higher than that in the untreated group (P <0.05). However, there was no difference in the T concentration between the two groups. The concentration of LIF in the treatment group was significantly higher than that before treatment (P <0.05); the concentration of T did not change obviously. (3) The relationship between follicular development and the changes of LIF and T concentrations after medication intervention: The follicular fluid LIF concentration increased by (16.3 ± 3.2) ng / L, while the immature increased by 7.4 ± 1.5) ng / L, the difference was statistically significant (P <0.05). The concentration of T in mature follicles decreased more than that in immature ones (P <0.05). Conclusion: Delta-35 can improve follicular fluid development may be related to changes in follicular leukemia inhibitory factor and testosterone levels.